Body height decreased adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 10,657 adverse event reports that record the MedDRA preferred term Body height decreased. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 174 reports in the 12 months to June 2026 and 276 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 1 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 99 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Body height decreased name as a suspect product, in order of name
Drug	Class	Reports with this term
Aclasta		101
Actemra	Interleukin-6 receptor antagonist	31
Actonel	Bisphosphonate	25
Alendronate sodium	Bisphosphonate	132
Anastrozole	Aromatase inhibitor	27
Apixaban	Factor Xa inhibitor	36
Arava	Antirheumatic agent	41
Arimidex	Aromatase inhibitor	82
Atenolol	beta-Adrenergic blocker	121
Atorvastatin		27
Atorvastatin calcium	HMG-CoA reductase inhibitor	35
Avonex	Interferon beta	32
Bevespi Aerosphere	Anticholinergic	33
Bextra		33
Boniva		48
Brilinta	P2Y12 platelet inhibitor	70
Budesonide Formoterol Glycopyrronium		32
Bydureon		140
Bydureon Bcise		126
Byetta	GLP-1 receptor agonist	83
Celebrex	Nonsteroidal anti-inflammatory drug	208
Chantix	Partial cholinergic nicotinic agonist	68
Cialis	Phosphodiesterase 5 inhibitor	192
Citalopram	Serotonin reuptake inhibitor	33
Cosentyx	Interleukin-17A antagonist	46
Crestor	HMG-CoA reductase inhibitor	245
Detrol	Cholinergic muscarinic antagonist	46
Dexamethasone	Corticosteroid	25
Diclofenac	Nonsteroidal anti-inflammatory drug	36
Dilantin	Anti-epileptic agent	55
Duragesic		56
Duragesic-100		77
Effexor	Serotonin and norepinephrine reuptake inhibitor	26
Eliquis	Factor Xa inhibitor	185
Enbrel	Tumor necrosis factor blocker	78
Evista	Estrogen Agonist/Antagonist	476
Exelon	Cholinesterase inhibitor	51
Faslodex	Estrogen receptor antagonist	33
Finasteride	5-alpha reductase inhibitor	25
Forteo	Parathyroid hormone analog	576
Fosamax	Bisphosphonate	239
Fosamax Plus D		56
Fulvestrant	Estrogen receptor antagonist	28
Gabapentin	Anti-epileptic agent	53
Gilenya	Sphingosine 1-phosphate receptor modulator	39
Humalog	Insulin analog	40
Human immunoglobulin g	Human immunoglobulin G	57
Human Immunoglobulin G Hyaluronidase Recombinant Human		35
Humira		240
Humulin N	Insulin	36
Ibrance	Kinase inhibitor	186
Icatibant	Bradykinin B2 receptor antagonist	44
Indacaterol and Glycopyrrolate		28
Lansoprazole	Proton pump inhibitor	34
Lipitor	HMG-CoA reductase inhibitor	204
Lisinopril	Angiotensin converting enzyme inhibitor	154
Lyrica		576
Metformin	Biguanide	53
Methotrexate	Folate analog metabolic inhibitor	70
Metoprolol	beta-Adrenergic blocker	44
Metoprolol succinate	beta-Adrenergic blocker	57
Metoprolol tartrate	beta-Adrenergic blocker	47
Neurontin		98
Nexium	Proton pump inhibitor	406
Nexium 24HR	Proton pump inhibitor	52
Norvasc	Calcium channel blocker	33
Ocrevus	CD20-directed cytolytic antibody	37
Omeprazole	Proton pump inhibitor	129
Orencia	Selective T cell costimulation modulator	63
Pomalyst	Thalidomide analog	81
Prednisone	Corticosteroid	91
Premarin	Estrogen	118
Prilosec	Proton pump inhibitor	117
Prilosec OTC	Proton pump inhibitor	41
Prolia	RANK ligand inhibitor	464
Pulmicort Flexhaler	Corticosteroid	55
Remicade	Tumor necrosis factor blocker	92
Revatio	Phosphodiesterase 5 inhibitor	39
Revlimid	Thalidomide analog	532
Rituxan	CD20-directed cytolytic antibody	26
Sandostatin LAR Depot		57
Seroquel	Atypical antipsychotic	48
Simponi	Tumor necrosis factor blocker	50
Symbicort	Corticosteroid	535
Synthroid	l-Thyroxine	28
Tacrolimus	Calcineurin inhibitor immunosuppressant	30
Takhzyro	Plasma kallikrein inhibitor	30
Tiotropium bromide	Anticholinergic	59
Toprol Xl	beta-Adrenergic blocker	75
Toviaz		39
Tudorza Pressair	Anticholinergic	146
Vedolizumab	Integrin receptor antagonist	45
Viagra	Phosphodiesterase 5 inhibitor	28
Vyndamax		84
Xalatan	Prostaglandin analog	39
Xarelto	Factor Xa inhibitor	129
Xeljanz	Janus kinase inhibitor	298
Xolair	Anti-IgE	45
Zoloft	Serotonin reuptake inhibitor	46

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 59 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Body height decreased name, in order of name
Class	Reports with this term
5-alpha reductase inhibitor	25
Amide local anesthetic	43
Aminosalicylate	25
Angiotensin 2 receptor blocker	87
Angiotensin converting enzyme inhibitor	171
Anti-epileptic agent	124
Anti-IgE	45
Anticholinergic	242
Antimalarial	41
Antirheumatic agent	43
Aromatase inhibitor	143
Aromatic amino acid	35
Atypical antipsychotic	80
Benzodiazepine	46
beta-Adrenergic blocker	357
Biguanide	74
Bisphosphonate	428
Bradykinin B2 receptor antagonist	47
Calcineurin inhibitor immunosuppressant	30
Calcium channel blocker	52
CD20-directed cytolytic antibody	87
Cholinergic muscarinic antagonist	48
Cholinesterase inhibitor	57
Corticosteroid	785
Estrogen	149
Estrogen Agonist/Antagonist	476
Estrogen receptor antagonist	61
Factor Xa inhibitor	352
Folate analog metabolic inhibitor	88
GLP-1 receptor agonist	102
Histamine-2 receptor antagonist	40
HMG-CoA reductase inhibitor	529
Human immunoglobulin G	63
Insulin	81
Insulin analog	52
Integrin receptor antagonist	47
Interferon beta	32
Interleukin-17A antagonist	46
Interleukin-6 receptor antagonist	33
Janus kinase inhibitor	321
Kinase inhibitor	317
l-Thyroxine	43
Nonsteroidal anti-inflammatory drug	383
Opioid agonist	91
P2Y12 platelet inhibitor	90
Parathyroid hormone analog	591
Partial cholinergic nicotinic agonist	68
Phosphodiesterase 4 inhibitor	34
Phosphodiesterase 5 inhibitor	259
Plasma kallikrein inhibitor	30
Prostaglandin analog	57
Proton pump inhibitor	804
RANK ligand inhibitor	475
Selective T cell costimulation modulator	71
Serotonin and norepinephrine reuptake inhibitor	89
Serotonin reuptake inhibitor	99
Sphingosine 1-phosphate receptor modulator	39
Thalidomide analog	613
Tumor necrosis factor blocker	256

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Body height decreased, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Body height decreased
Age	Reports	Share
Under 2	6	0.1%
2 to 11	40	0.4%
12 to 17	29	0.3%
18 to 44	269	2.5%
45 to 64	1,906	17.9%
65 to 74	2,194	20.6%
75 and over	2,580	24.2%
Age not given	3,633	34.1%

Sex of the patient in the reports that record Body height decreased
Sex	Reports	Share
Female	7,820	73.4%
Male	2,570	24.1%
Unknown or not given	267	2.5%

Age and sex are as the report gives them. 83.3% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Body height decreased: adverse event reports that record this term. https://reportedreactions.com/reaction/body-height-decreased/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 1 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 1 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Oct 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Body height decreased mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page